bs-1174R **[Primary Antibody]**

CDKN2A/p19ARF Rabbit pAb

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

DATASHEET

Host: Rabbit **Isotype:** IgG

Clonality: Polyclonal

GeneID: 12578 **SWISS:** P51480

Target: CDKN2A/p19ARF

Immunogen: KLH conjugated synthetic peptide derived from mouse CDKN2A/p19ARF: 65-169/169.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012].

Applications: **IHC-P** (1:100-500)
IHC-F (1:100-500)
IF (1:100-500)

Reactivity: Rat (predicted: Mouse)

Predicted MW.: 19 kDa

Subcellular Location: Cytoplasm ,Nucleus

VALIDATION IMAGES



Tissue/cell: Rat brain tissue; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37°C for 20 min; Incubation: Anti-CD2A2 Polyclonal Antibody, Unconjugated(bs-1174R) 1:500, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining



Tissue/cell: rat brain tissue; 4% Paraformaldehyde-fixed and paraffin-embedded; Antigen retrieval: citrate buffer (0.01M, pH 6.0), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37鈴?? for 20 min; Incubation: Anti-CD2A2 Polyclonal Antibody, Unconjugated(bs-1174R) 1:200, overnight at 4 掳C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining

SELECTED CITATIONS

- **[IF=12.5]** Wang Simeng. et al. Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR Mutant Non-Small Cell Lung Cancer. CANCER RES. 2024 Nov;: WB ;. 39514336
- **[IF=12.5]** Simeng Wang. et al.Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR-Mutant Non–Small Cell Lung Cancer.cancer research.2025 Feb 1;85(3):585-601. Western blot ;Mouse. 39514336
- **[IF=2.33]** Liang, Wu, et al. "Knockdown BMI1 expression inhibits proliferation and invasion in human bladder cancer T24 cells." Molecular and cellular biochemistry (2013): 1-9. WB ;="Human". 23820733